Answers are grounded in this paper and cite their sources.
Case-control study compares lipid profiles in CKD patients and healthy controls, highlighting dyslipidemia prevalence.
Introduction: Chronic Kidney Disease (CKD) is a progressive condition characterized by declining renal function, commonly resulting from diabetes, hypertension, and other comorbidities. It is associated with significant metabolic disturbances, particularly dyslipidemia, which contributes to increased cardiovascular risk. Dyslipidemia in CKD typically presents as elevated triglycerides, low HDL, and variable LDLlevels due to impaired lipid metabolism. This study investigates the lipid profile patterns among CKD patients and their implications on disease severity and cardiovascular outcomes. Objectives: To determine the pattern of dyslipidemia and the spectrum of dyslipidemia among chronic kidney disease patients and comparing the patterns with healthy controls and to investigate the relationship between dyslipidemia and the severity of chronic kidney disease. Methods: This hospital-based case-control study was conducted in Barabanki and Faizabad, India, from November 2022 to October 2025. A total of 100 participants were enrolled—50 CKD patients and 50 age- and sex-matched healthy controls. Data collection included clinical assessments, fasting lipid profiles, and kidney function tests. Exclusion criteria involved conditions or medications that could independently affect lipid levels. Lipid parameters were analyzed using enzymatic methods and Friedewald's formula; eGFR was calculated using the Cockcroft-Gault equation. Results: CKD patients showed significantly higher levels of total cholesterol, triglycerides, LDL, and VLDL, with lower HDL compared to controls (p<0.0001). Dyslipidemia prevalence was 90% for cholesterol, 86% for triglycerides, and 62% for low HDL. Advanced CKD stages correlated with more severe lipid abnormalities and greater cardiovascular risk. Conclusion: The findings underscore the high prevalence of dyslipidemia in CKD and its association with disease progression. Routine lipid monitoring and early intervention are essential to reduce cardiovascular complications and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: